|
EQS-News: Vita 34 AG
/ Key word(s): Personnel
Vita 34 downsizes Management Board until further notice
Leipzig, 2 January 2024 – Vita 34 AG, the leading cell bank in Europe and the third largest in the world, is making changes to its Management Board. Chief Financial Officer Dirk Plaga has resigned from the Management Board of Vita 34 AG as of 31 December 2023 in order to pursue new professional challenges. The resignation from the Management Board is by mutual agreement. Mr. Plaga has headed the finance department since August 2022. The Chairman of the Supervisory Board of Vita 34 AG, Dr. Alexander Granderath, expressly thanks Mr. Plaga for his commitment to the benefit of the company. The entire Supervisory Board wishes Mr. Plaga all the best for his future professional development. "On behalf of the Management Board, I would like to thank Dirk Plaga for the cooperation over the past one and a half years," explains Jakub Baran, CEO of Vita 34 AG. The Management Board will be reduced to two members until further notice. In the coming months, the company will decide in which constellation the Management Board will work in the future. Contact: Vita 34 was founded in Leipzig in 1997 and is today by far the leading cell bank in Europe and the third largest worldwide. As Europe's first private cord blood bank and a pioneer in cell banking, the company has since offered collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissues as a full-service cryopreservation provider. Due to the expansion of its business model following the merger with PBKM, the company plans to invest in cell and gene therapies and CDMO. The body's own cells are a valuable starting material for medical cell therapy and are kept alive in the vapor of liquid nitrogen. Customers from around 50 countries have already ensured the health of their families with more than 930,000 units of stored biological material at Vita 34.
02.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Vita 34 AG |
| Deutscher Platz 5a | |
| 04103 Leipzig | |
| Germany | |
| Phone: | +49(0341)48792-40 |
| Fax: | +49(0341)48792-39 |
| E-mail: | ir@vita34.de |
| Internet: | www.vita34.de |
| ISIN: | DE000A0BL849 |
| WKN: | A0BL84 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1806485 |
| End of News | EQS News Service |
|
|
1806485 02.01.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
